Bacterial Infections
Infections by bacteria, general or unspecified.
Subtype terms (12)
More specific conditions that are subtypes of Bacterial Infections in the MeSH hierarchy.
- Bacteremia
71 drugs (56 approved, 15 experimental)
- Bacterial Zoonoses
- Central Nervous System Bacterial Infections
2 drugs approved
- Endocarditis, Bacterial
13 drugs (11 approved, 2 experimental)
- Eye Infections, Bacterial
9 drugs (8 approved, 1 experimental)
- Fournier Gangrene
4 drugs (3 approved, 1 experimental)
- Gram-Negative Bacterial Infections
20 drugs (13 approved, 7 experimental)
- Gram-Positive Bacterial Infections
31 drugs (24 approved, 7 experimental)
- Pneumonia, Bacterial
62 drugs (47 approved, 15 experimental)
- Sexually Transmitted Diseases, Bacterial
1 drug approved
- Skin Diseases, Bacterial
42 drugs (33 approved, 9 experimental)
- Vaginosis, Bacterial
79 drugs (36 approved, 43 experimental)
Drugs by status
Approved for this indication (69)
- metronidazole
- isopropyl alcohol
- tetracycline
- ampicillin
- cilastatin
- levonadifloxacin
- trifluoromethyldichlorocarbanilide
- sulfamerazine
- neomycin
- phenoxymethylpenicillin
- fusidic acid
- cefpirome
- temocillin
- virginiamycin
- meticillin
- triclosan
- rolitetracycline
- enterococcus faecium
- domiphen
- ceftazidime
- gentamicin
- ethanol
- linezolid
- benzathine penicillin
- bacillus licheniformis
- gentian violet
- benzylpenicillin
- moxalactam
- prodoxal
- procaine benzylpenicillin
- +39 more
Phase 4 trials (62)
- clavulanate
- obiltoxaximab
- doxycycline
- meropenem
- chlorhexidine
- cefazolin
- vancomycin
- cefiderocol
- rabeprazole
- octenidine
- azithromycin
- tegafur
- propanolol
- ophiocordyceps sinensis
- fosfomycin
- nifedipine
- anthrax vaccine, adsorbed
- acetylcysteine
- bismuth
- contezolid
- ilaprazole
- iohexol
- moxifloxacin
- clarithromycin
- ciprofloxacin
- tinidazole
- ertapenem
- doripenem
- dalbavancin
- sulbactam
- +32 more
Phase 3 trials (58)
- pneumococcal 13-valent conjugate vaccine
- cefepime
- pantoprazole
- acacia
- nystatin
- rifabutin
- rotavirus vaccine, live, oral, pentavalent
- tedizolid phosphate
- haemophilus influenzae type b conjugate vaccine
- human fecal microbiota
- rifaximin
- Tetanus and diphtheria toxoids adsorbed
- sulfamethoxazole
- clofazimine
- dicloxacillin
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- lignin
- sodium chloride
- hepatitis b vaccine (recombinant)
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- tobramycin
- trimethoprim
- nacubactam
- delafloxacin
- Bismuth Subcitrate Potassium
- avibactam
- Monovalent group C meningococcal vaccine
- omadacycline
- guava leaves extract
- preforpro
- +28 more
Phase 2 trials (28)
- cαstx1
- lactoferrin
- sildenafil
- p128
- gepotidacin
- Afabicin
- linopristin
- cαstx2
- tnp-2092
- pravibismane
- lefamulin
- lanopepden
- group b streptococcus trivalent vaccine
- DUOFAG
- ar51
- brilacidin
- afn-12520000
- flopristin
- niclosamide
- mucoid exopolysaccharide p. aeruginosa immune globulin
- inulin
- sorbitol
- wrair-pam-cf1
- probenecid
- gbs trivalent vaccine
- amivantamab-vmjw
- atovaquone
- lactobacillus brevis
Phase 1 trials (54)
- lauric acid
- gsk3342830
- qpx2015
- anacaulase
- td-1607
- op0595
- ethinyl estradiol
- polyglucosamine
- biapenem
- silver nanoparticles
- qpx2014
- tp-271
- itraconazole
- fluoropropyl-trimethoprim
- polymyxin b sulfate
- qpx7728
- etx2514
- choline geranate
- sa3ag
- calcium hydroxide
- cefotaxime
- qpx7831
- gsk580416
- pf02413873
- btz-043
- ceftibuten
- ketoconazole
- lincomycin
- solithromycin
- tqd3606
- +24 more
Other trials (52)
- hypochlorous acid
- iclaprim
- cethromycin
- plazomicin
- bifidobacterium bifidum
- almecillin
- triclocarban
- EcoActive
- benzalkonium
- igy
- autologous microbiome
- bifidobacterium infantis
- vitamin d3
- flomoxef
- lactobacillus rhamnosus
- cow milk
- alteplase
- prulifloxacin
- igm enriched immunoglobulins
- fish oil
- fosmidomycin
- lactobacillus reuteri
- lapyrium
- acadesine
- streptococcus salivarius
- hydrogen peroxide
- albendazole
- silver fluoride
- gentisic acid ethanolamide
- cloxacillin
- +22 more
Organizations
Organization Involved with Phase 4 Indications (66)
- Theravance
- Pfizer
- Allergan
- GlaxoSmithKline
- National Institutes of Health (NIH)
- Fondo Nacional de Desarrollo Científico y Tecnológico, Chile
- National Cancer Institute, Egypt
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Roma La Sapienza
- Rabin Medical Center
- Aarhus University
- Medical University of Graz
- Tzu Chi University
- Case Western Reserve University
- Changi General Hospital
- University of London
- Dartmouth University
- Hospital Barros Luco Trudeau
- Katholieke Universiteit Leuven
- Metro Health, Michigan
- Osaka University
- Queen's University, Belfast
- Radboud University
- The Baruch Padeh Medical Center, Poriya
- Universidad Complutense de Madrid
- University of Milan
- University of Nottingham
- University of Padova
- University of Bern
- University of Birmingham
- +36 more
Organization Involved with Phase 3 Indications (44)
- PathoGenesis
- Peninsula Pharmaceuticals
- Basilea Pharmaceutica
- Green Cross Corporation
- Forest Laboratories
- Stiefel Laboratories
- Aventis
- Sanofi
- Sanofi-Aventis
- Aridis Pharmaceuticals, Inc.
- Cubist
- Inmunotek S.L.
- Paratek Pharmaceuticals Inc
- Epicentre
- National Cancer Institute (NCI)
- Harvard University
- Duke University
- University of Washington
- Institute of Tropical Medicine, Belgium
- Oregon Health and Science University
- Partners in Health
- Skaraborg Hospital
- Shengjing Hospital
- Universidad Autonoma de Madrid
- Universidad de Antioquia
- University of Bergen
- Yale University
- Aga Khan University
- All India Institute of Medical Sciences
- Food and Drug Administration
- +14 more
Organization Involved with Phase 2 Indications (31)
- Debiopharm
- Shionogi
- AM-Pharma
- Novartis
- Union Therapeutics
- GangaGen, Inc.
- Glaxo Wellcome
- Manipal Acunova Ltd.
- MerLion Pharmaceuticals GmbH
- Microbion Corporation
- Nabriva Therapeutics AG
- Affinium Pharmaceuticals, Ltd
- MicuRx
- Thallion Pharmaceuticals
- National Center for Research Resources (NCRR)
- Robert S Berman MD
- University of Pennsylvania
- University of Michigan
- University of Zurich
- Kuwait University
- University of Turku
- Vanderbilt University
- Department of Defense
- Medpace, Inc.
- Medical University of Vienna
- National University of Singapore
- Regional Hospital Heilig Hart, Tienen, Belgium
- Department of Health and Human Services
- LFB Biotechnologies, SAS
- Innovation Pharmaceuticals
- +1 more
Organization Involved with Phase 1 Indications (43)
- Durata
- The Medicines Company
- Roche
- AstraZeneca
- Cempra Inc
- Laboratoires Thea
- Meiji Seika Pharma Co., Ltd.
- Parexel
- Sponsor GmbH
- VenatoRx Pharmaceuticals, Inc.
- Verisfield UK Ltd. Greek Branch
- The EMMES Corporation
- Telethon Kids Institute
- China Academy of Chinese Medical Sciences
- Hoosier Cancer Research Network
- Institut National de la Santé Et de la Recherche Médicale, France
- University of Louisville
- University of Melbourne
- University of Tennessee
- Wayne State University
- Mayo Clinic
- Tsinghua University
- University of Auckland
- Hammersmith Medicines Research
- Nucleus Network Ltd
- Covance
- Tetraphase Pharmaceuticals
- University of Queensland
- International Pharmaceutical Research Center, Jordan
- Al Azhar University
- +13 more
Organization Involved with Other Experimental Indications (19)
- Danisco
- Hamad Medical Corporation
- myTomorrows
- Lallemand SAS
- NIZO Food Research
- The Netherlands Asthma Foundation
- Centre d'Appui à la lutte contre la Maladie
- Johns Hopkins University
- University of Oklahoma
- Utrecht University
- Groupe Hospitalier Paris Saint Joseph
- Institute of Liver and Biliary Sciences, India
- Centre National d'Appui à la Lutte contre la Maladie, Mali
- Kowng Wah Hospital
- International Trachoma Initiative
- Government of Hong Kong
- China Medical University
- Imperial College London
- Qatar University